Global Blood Therapeutics (GBT) Reports Q1 Loss of $0.60/Share

Global Blood Therapeutics (NASDAQ: GBT) reported Q1 EPS of ($0.60), versus ($0.56) reported last year.

"We continue to make important progress advancing our lead product candidate, GBT440, across both our sickle cell disease (SCD) and idiopathic pulmonary fibrosis (IPF) indications,” said Ted W. Love, M.D., president and chief executive officer of GBT. “We are focused on activating new clinical trial sites for our pivotal HOPE Study to support ongoing enrollment and look forward to highlighting preliminary results from our Phase 2a study of GBT440 in adolescents, 12-17 years old, at the Congress of the European Hematology Association (EHA). Additionally, we remain on track to report data from our ongoing studies supporting our hypoxemia program later this year.”

For earnings history and earnings-related data on Global Blood Therapeutics (GBT) click here.

You May Also Be Interested In

• Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Oceanfirst Financial (OCFC) Tops Q1 EPS by 3c